logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5401.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5401.produseast1
Journal Article
|Commentary

Seasonal malaria chemoprevention: successes and missed opportunities

Coldiron ME, von Seidlein L, Grais RF
Download

Similar Content
Loading...
Loading...
Loading...
Seasonal malaria chemoprevention: successes and missed opportunities | Journal Article / Commentary | MSF Science Portal
Abstract
Seasonal malaria chemoprevention (SMC) was recommended in 2012 for young children in the Sahel during the peak malaria transmission season. Children are given a single dose of sulfadoxine/pyrimethamine combined with a 3-day course of amodiaquine, once a month for up to 4 months. Roll-out and scale-up of SMC has been impressive, with 12 million children receiving the intervention in 2016. There is evidence of its overall benefit in routine implementation settings, and a meta-analysis of clinical trial data showed a 75% decrease in clinical malaria compared to placebo. SMC is not free of shortcomings. Its target zone includes many hard-to-reach areas, both because of poor infrastructure and because of political instability. Treatment adherence to a 3-day course of preventive treatment has not been fully documented, and could prove challenging. As SMC is scaled up, integration into a broader, community-based paradigm which includes other preventive and curative activities may prove beneficial, both for health systems and for recipients.

Subject Area

malariavector borne diseases

Languages

English
DOI
10.1186/s12936-017-2132-1
Published Date
28 Nov 2017
PubMed ID
29183327
Journal
Malaria Journal
Volume | Issue | Pages
Volume 16, Issue 1, Pages 481
Issue Date
2017-11-28
Dimensions Badge